Lupin Subsidiary VISUfarma Signs ₹832 Cr Licensing Deal with Visus for YUVEZZI in Europe
Lupin Limited subsidiary VISUfarma B.V. signs ₹832 Cr deal with Visus Therapeutics to commercialize YUVEZZI in Europe, targeting the presbyopia treatment market.
